Karyopharm Therapeutics INC Form 4 insider transactions

Richard Paulson, CEO of Karyopharm Therapeutics, sold 4,055 shares of common stock to cover withholding tax liabilities incurred upon the vesting of restricted stock units.

Karyopharm Therapeutics CEO Richard Paulson sold 3,620 shares of common stock at $0.81 per share to cover tax obligations related to vesting restricted stock units.

Richard Paulson, CEO of Karyopharm Therapeutics, sold 3,675 shares of common stock on November 5, 2024, to cover withholding tax liabilities.

Richard A. Paulson, CEO of Karyopharm Therapeutics, sold 3,607 shares of common stock to cover withholding tax liabilities.

Michael Mano, SVP, General Counsel & Secretary of Karyopharm Therapeutics, sold 3,971 shares of common stock to cover withholding tax liability.

Richard Paulson, CEO of Karyopharm Therapeutics, sold 3,667 shares of common stock to cover withholding tax liabilities.

Michael Mason, EVP, CFO & Treasurer of Karyopharm Therapeutics, sold 7,050 shares of common stock at $0.7218 per share to cover withholding tax obligations.

Sohanya Cheng, EVP & Chief Commercial Officer of Karyopharm Therapeutics, reports selling shares to cover withholding tax liabilities related to vested restricted stock units.

Richard Paulson, CEO of Karyopharm Therapeutics, sold 3,608 shares of common stock on August 6, 2024, to cover withholding tax liabilities.

Stuart Poulton, EVP and Chief Development Officer of Karyopharm Therapeutics, sold 2,883 shares of common stock to cover withholding tax liabilities.

Richard Paulson, CEO of Karyopharm Therapeutics, sold 3,616 shares of common stock to cover withholding tax liabilities.

Director Deepika Pakianathan reports selling Karyopharm Therapeutics (KPTI) shares in multiple transactions between June 5th and June 7th, 2024.

Michael Mason, EVP, CFO & Treasurer of Karyopharm Therapeutics, sold 652 shares of common stock at $0.99 per share to cover withholding tax obligations.

Richard Paulson, CEO of Karyopharm Therapeutics, sold 3,592 shares of common stock on June 4, 2024, to cover withholding tax obligations.

Director Deepika Pakianathan reports multiple sales of Karyopharm Therapeutics (KPTI) common stock between May 31 and June 4, 2024.

Director Zhen Su acquired 50,587 nonstatutory stock options in Karyopharm Therapeutics on May 29, 2024.

Deepika Pakianathan, a director of Karyopharm Therapeutics, acquired 69,000 nonstatutory stock options on May 29, 2024.

Director Chen Schor acquired 69,000 nonstatutory stock options in Karyopharm Therapeutics on May 29, 2024.

Director Mansoor Raza Mirza acquired 69,000 nonstatutory stock options in Karyopharm Therapeutics on May 29, 2024.

Christy J. Oliger, a director of Karyopharm Therapeutics Inc., acquired 69,000 nonstatutory stock options on May 29, 2024.

Barry E. Greene, a director at Karyopharm Therapeutics Inc., acquired 69,000 nonstatutory stock options on May 29, 2024.

Director Garen Bohlin acquired 69,000 nonstatutory stock options in Karyopharm Therapeutics, vesting fully on May 29, 2025.

Richard Paulson, CEO of Karyopharm Therapeutics, sold 3,576 shares of common stock on May 6, 2024, to cover withholding tax liabilities related to vested restricted stock units.

Reshma Rangwala, EVP & Chief Medical Officer of Karyopharm Therapeutics, sold 6,789 shares of common stock on April 22, 2024, to cover withholding tax liabilities.

Richard Paulson, CEO of Karyopharm Therapeutics, sold 3,563 shares of common stock on April 4, 2024, to cover withholding tax liabilities.

Karyopharm Therapeutics CEO Richard Paulson sold 3,573 shares of common stock on March 5, 2024, to cover withholding tax liabilities.

Reshma Rangwala, EVP & Chief Medical Officer of Karyopharm Therapeutics, sold shares of common stock to cover withholding tax liabilities related to vesting restricted stock units.

Stuart Poulton, EVP and Chief Development Officer of Karyopharm Therapeutics, sold shares to cover withholding tax liabilities related to vesting restricted stock units.

Michael Mason, EVP, CFO & Treasurer of Karyopharm Therapeutics, sold shares of common stock on February 29, 2024, and March 1, 2024, to cover withholding tax liabilities.

Michael Mano, SVP, General Counsel & Secretary of Karyopharm Therapeutics, sold shares of common stock on February 29, 2024, and March 1, 2024, to cover withholding tax liabilities.